Our analysis confirmed the usefulness of uPA and PAI-1 biomarkers for assessing prognosis in patients with node-negative, HR-positive/HER2-negative early breast cancers treated with adjuvant endocrine therapy. Here, ERBB2 is linked to breast cancer.